China Kidney Cancer Therapeutics Market Analysis

China Kidney Cancer Therapeutics Market Executive Summary

China Kidney Cancer Therapeutics Market is at around $505.64 Mn in 2023 and is projected to reach $788.55 Mn in 2030, exhibiting a CAGR of 6.36% during the forecast period.

The emergence of malignant tumors in the kidneys is a characteristic of kidney cancer. Renal cell carcinoma primarily affects the elderly, typically those in their 50s to 70s. Blood in the urine, pain in the back or flanks, an abdominal mass or lump, exhaustion, appetite loss, inadvertent weight loss, and lack of appetite are typical symptoms. The exact cause of kidney cancer is often unknown, although risk factors such as obesity, smoking, high blood pressure, and family history can increase the likelihood of developing the disease. Depending on the stage and severity of the disease, there are a variety of treatment options available, such as immunotherapy, surgery, targeted therapy, and occasionally radiation therapy. Kidney transplantation is the most common type of treatment for persistent renal disease. Kidney cancer is treated by kidney excision surgery when the disease has spread to the point where it needs to be removed.

China is the second largest pharmaceutical market in the world. There are approximately 46,900 new cases of kidney cancer patients in China per year, according to Chinese Society of Clinical Oncology. Even now, there is still a significant disparity in the quality of medical care provided in different parts of China. For the treatment of more complicated ailments, many people from inland regions and rural areas must travel hundreds of kilometers to the provincial capitals or to famous hospitals in Beijing, Shanghai, and Tianjin. A focused ultrasound system has also been approved in China and in Europe for the treatment of kidney cancer. The market is growing due to the Increased Incidence of Kidney Diseases, Demand for Immunotherapies, Government initiatives, and funding. However Regulatory Hurdles, Adverse effects, and High cost of treatment restrict the growth and potential of the market.

Pfizer Inc. (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.) are key players in the China Kidney Cancer Therapeutics Market.

Market Dynamics

Market Growth Drivers

Increased Incidence of Kidney Diseases: The increasing incidence of chronic kidney disease is majorly responsible for driving the growth of the kidney cancer drugs market. Changes in lifestyle of people, consumption of tobacco, and unhealthy diet are some factors responsible for increasing the incidence of chronic kidney disease.

Demand for Immunotherapies: By manipulating the immune system, this novel strategy targets and destroys cancerous cells. As immunotherapy strengthens the body's natural defences, it has demonstrated effective results in treating kidney cancer. This gives patients hope, especially when traditional medicines have little or no effect. The approval of MSD's anti-PD-1 medication, KEYTRUDA (pembrolizumab), by the Drug Controller General of India (DCGI) in October 2023 was a significant development.

Government initiatives and funding: Significant market growth is also being driven by government initiatives and funding that are aimed at kidney problems. These kinds of initiatives seek to strengthen public health services, the economy, and disease surveillance. They also seek to increase awareness. In 2015, the Chinese government unveiled a new five-year strategy aimed at achieving "Healthy China 2020" in order to counteract the declining health of its people. With a predicted 30% increase in beds at public hospitals and a 100% increase in beds at private hospitals, this plan advocated for an expansion of the medical infrastructure, particularly private hospitals. Nivolumab, a novel medication for kidney cancer, was introduced in 2022 by the Clinical Hospital of the Faculty of Medicine of Ribeirao Preto in collaboration with Bristol Myers Squibb and the São Paulo Research Foundation.

Market Restraints

Regulatory Hurdles: Regulatory barriers are among the most significant barriers to the renal cancer medication market. Longer approval periods for new medicines are a common result of these strict regulatory procedures, even if they are essential for patient safety and medication efficacy. The market availability of novel medicines is significantly delayed by these processes, which necessitate lengthy clinical trials and intricate documentation requirements.

Adverse effects: The significant adverse effects of the medications used for the treatment of can kidney cancer can hinder the market's expected rate of growth. Rash, fever, and nausea are examples of side effects that could prevent the market from expanding.

High cost of treatment: The high expense of cutting-edge pharmacological therapies and the inequalities in the healthcare system impede the general accessibility and affordability of kidney cancer medications. This restriction makes it difficult for patients to obtain innovative treatments, which could impede market expansion and make it more difficult to address the growing incidence of kidney cancer. A cost-effectiveness study is necessary in order to help policymakers allocate their limited resources more effectively, as seen by the rising expenses associated with cancer treatment.

Regulatory Landscape and Reimbursement Scenario

China's health insurance program will be supervised by the Health Security Administration (HSA). In addition to centralizing the purchase of drugs and medical devices, the HSA will control medication prices and reimbursement guidelines. All imported medications and medical devices must register or undergo a notification filing process with the National Medical Products Administration (NMPA, formerly known as CFDA) before being marketed or distributed in the Chinese market. Good Clinical Practice (GCP), Good Manufacturing Practices (GMP) abroad, the "Generic Drugs Quality Consistency Evaluation" (GQCE), and the validation of pharmaceutical manufacturing procedures have been in place to in order to monitor production of generics.

China's healthcare system has advanced significantly in recent years, and in order to achieve even greater progress, many parts of the current medical care system are still being examined.

The healthcare insurance system established by the Chinese government provides benefits to approximately 1.36 Bn people and covers about 96% of the population. Additionally, there is a large array of private healthcare solutions accessible, and it is possible to add private insurance to public health insurance.

Competitive Landscape

Key Players

Here are some of the major key players in the China Kidney Cancer Therapeutics Market:

• Pfizer Inc (U.S.)
• AstraZeneca (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Dr. Reddy's Laboratories Ltd (India)
• Sun Pharmaceutical Industries Ltd (India)
• Novartis AG (Switzerland)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)